English

CELL THERAPEUTICS INC

EDGAR

CTIC Quarterly report (10-Q) · filed 2023-05-15

148 filing records in this dataset, filed from 1996-08-14 to 2023-05-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

24.1 million USD

2023 Q1 · USD

Exact inputs and evidence

Revenue: 24116000 USD Source

Operating margin

-38.28%

2023 Q1 · %

Exact inputs and evidence

Operating Income: -9232000 USD Source
Revenue: 24116000 USD Source

Operating cash flow

-31.1 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -31098000 USD Source

Cash and cash equivalents: 24.2 million USD 2023-03-31 Source
Exact value

24209000 USD
Long-term debt including current maturities: 47.9 million USD 2022-12-31 Source
Exact value

47943000 USD
Shares outstanding: 132 million shares 2023-03-31 Source
Exact value

131879976 shares

Reported share-count change

31.07% · 31.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

100618348 shares · 2022-03-31· Source
131879976 shares · 2023-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

75.8 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Revenue: 12329000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 18241000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 53948000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 32865000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 24116000 USD · 2023-01-01 – 2023-03-31 Source

Net income

-69.2 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Net income: -22654000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -15705000 USD · 2022-07-01 – 2022-09-30 Source
Net income: -92992000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -75534000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -13422000 USD · 2023-01-01 – 2023-03-31 Source

Operating cash flow

-82.3 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Operating cash flow: -50221000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -29977000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -65684000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -50221000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -81194000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -65684000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -31098000 USD · 2023-01-01 – 2023-03-31 Source

Capital expenditure

0 USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Capital expenditure: 0 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-12-31 Source
Capital expenditure: 0 USD · 2019-01-01 – 2019-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-05-15.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2022-12-31
Operating income: 11 of 11 periods available· newest 2022-12-31
Net income: 11 of 11 periods available· newest 2022-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
Capital expenditure: 10 of 11 periods available· newest 2021-12-31
Total assets: 11 of 11 periods available· newest 2022-12-31
Total liabilities: 11 of 11 periods available· newest 2022-12-31
Current assets: 11 of 11 periods available· newest 2022-12-31
Current liabilities: 11 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 5 of 11 periods available· newest 2022-12-31
Shares outstanding: 11 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 53.95 million

Prior period

USD 0

2021-01-01 – 2021-12-31
Current period

USD 53.95 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

53948000 − 0 = 53948000 USD

0 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
53948000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CELL THERAPEUTICS INC · 2022-12-31 CELL THERAPEUTICS INC (edgar:891293) Year-over-year change in Revenue: 53948000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 53948000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#675198 Filing: 000089129323000011 Input fundies:Revenue: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#676406 Filing: 000089129323000011
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 4.92 million

Prior period

−USD 97.91 million

2021-01-01 – 2021-12-31
Current period

−USD 92.99 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-92992000 − -97908000 = 4916000 USD

-97908000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-92992000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CELL THERAPEUTICS INC · 2022-12-31 CELL THERAPEUTICS INC (edgar:891293) Year-over-year change in Net income: 4916000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -92992000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#1489299 Filing: 000089129323000011 Input fundies:NetIncome: -97908000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#1490661 Filing: 000089129323000011
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.7 million

Prior period

−USD 84.89 million

2021-01-01 – 2021-12-31
Current period

−USD 81.19 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-81194000 − -84889000 = 3695000 USD

-84889000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-81194000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CELL THERAPEUTICS INC · 2022-12-31 CELL THERAPEUTICS INC (edgar:891293) Year-over-year change in Operating cash flow: 3695000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -81194000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#929432 Filing: 000089129323000011 Input fundies:OperatingCashFlow: -84889000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#930481 Filing: 000089129323000011
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 53.95 million 100% of revenue
Operating costs Derived USD 133.75 million 248% of revenue
Operating income −USD 79.8 million −148% of revenue
Tax, interest and other Derived USD 13.2 million 24% of revenue
Net income −USD 92.99 million −172% of revenue

Cash

Operating cash flow −USD 81.19 million −151% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 220% of revenue.
2014 Operating loss: operating costs were 244% of revenue.
2015 Operating loss: operating costs were 824% of revenue.
2016 Operating loss: operating costs were 186% of revenue.
2017 Operating loss: operating costs were 257% of revenue.
2018 Operating loss: operating costs were 225% of revenue.
2019 Operating loss: operating costs were 1,317% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 248% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	34678000	76204000 Derived	-41526000	1217000 Derived	-42743000	-37487000 Derived	Source 2013-01-01 – 2013-12-31: 34678000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -41526000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -42743000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -35830000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1657000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	60077000	146310000 Derived	-86233000	7134000 Derived	-93367000	-39883000 Derived	Source 2014-01-01 – 2014-12-31: 60077000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -86233000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -93367000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -39550000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 333000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	16116000	132782000 Derived	-116666000	2756000 Derived	-119422000	-95281000 Derived	Source 2015-01-01 – 2015-12-31: 16116000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -116666000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -119422000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -95203000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 78000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	57405000	106567000 Derived	-49162000	2847000 Derived	-52009000	-76817000 Derived	Source 2016-01-01 – 2016-12-31: 57405000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -49162000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -52009000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -76680000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 137000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	25146000	64665000 Derived	-39519000	1151000 Derived	-40670000	-39345000 Derived	Source 2017-01-01 – 2017-12-31: 25146000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -39519000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -40670000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -39296000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 49000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	26290000	59189000 Derived	-32899000	-3579000 Derived	-29320000	-39857000 Derived	Source 2018-01-01 – 2018-12-31: 26290000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -32899000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -29320000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -39824000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 33000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	3345000	44056000 Derived	-40711000	-691000 Derived	-40020000	-27822000 Derived	Source 2019-01-01 – 2019-12-31: 3345000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -40711000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -40020000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -27822000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	47769000 Derived	-47769000	4682000 Derived	-52451000	-42222000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -47769000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -52451000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -42205000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 17000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	95332000 Derived	-95332000	2576000 Derived	-97908000	-84889000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -95332000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -97908000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -84889000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	53948000	133745000 Derived	-79797000	13195000 Derived	-92992000	Unavailable	Source 2022-01-01 – 2022-12-31: 53948000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -79797000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -92992000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -81194000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 53.9M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	34678000	Revenue: 34678000 Open source
20142014-12-31	Revenue	60077000	Revenue: 60077000 Open source
20152015-12-31	Revenue	16116000	Revenue: 16116000 Open source
20162016-12-31	Revenue	57405000	Revenue: 57405000 Open source
20172017-12-31	Revenue	25146000	Revenue: 25146000 Open source
20182018-12-31	Revenue	26290000	Revenue: 26290000 Open source
20192019-12-31	Revenue	3345000	Revenue: 3345000 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	53948000	Revenue: 53948000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 34678000 Open source Revenue: 0 Open source
20142014-12-31	Year over year	73.2%	Revenue: 60077000 Open source Revenue: 34678000 Open source
20152015-12-31	Year over year	-73.2%	Revenue: 16116000 Open source Revenue: 60077000 Open source
20162016-12-31	Year over year	256.2%	Revenue: 57405000 Open source Revenue: 16116000 Open source
20172017-12-31	Year over year	-56.2%	Revenue: 25146000 Open source Revenue: 57405000 Open source
20182018-12-31	Year over year	4.5%	Revenue: 26290000 Open source Revenue: 25146000 Open source
20192019-12-31	Year over year	-87.3%	Revenue: 3345000 Open source Revenue: 26290000 Open source
20202020-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 3345000 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 53948000 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -147.9% 2022

Net margin -172.4% 2022

Free cash flow margin -831.7% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-119.7%	Operating Income: -41526000 Open source Revenue: 34678000 Open source
20142014-12-31	Operating margin	-143.5%	Operating Income: -86233000 Open source Revenue: 60077000 Open source
20152015-12-31	Operating margin	-723.9%	Operating Income: -116666000 Open source Revenue: 16116000 Open source
20162016-12-31	Operating margin	-85.6%	Operating Income: -49162000 Open source Revenue: 57405000 Open source
20172017-12-31	Operating margin	-157.2%	Operating Income: -39519000 Open source Revenue: 25146000 Open source
20182018-12-31	Operating margin	-125.1%	Operating Income: -32899000 Open source Revenue: 26290000 Open source
20192019-12-31	Operating margin	-1,217.1%	Operating Income: -40711000 Open source Revenue: 3345000 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -47769000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -95332000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	-147.9%	Operating Income: -79797000 Open source Revenue: 53948000 Open source
20132013-12-31	Net margin	-123.3%	Net Income: -42743000 Open source Revenue: 34678000 Open source
20142014-12-31	Net margin	-155.4%	Net Income: -93367000 Open source Revenue: 60077000 Open source
20152015-12-31	Net margin	-741%	Net Income: -119422000 Open source Revenue: 16116000 Open source
20162016-12-31	Net margin	-90.6%	Net Income: -52009000 Open source Revenue: 57405000 Open source
20172017-12-31	Net margin	-161.7%	Net Income: -40670000 Open source Revenue: 25146000 Open source
20182018-12-31	Net margin	-111.5%	Net Income: -29320000 Open source Revenue: 26290000 Open source
20192019-12-31	Net margin	-1,196.4%	Net Income: -40020000 Open source Revenue: 3345000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -52451000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -97908000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	-172.4%	Net Income: -92992000 Open source Revenue: 53948000 Open source
20132013-12-31	Free cash flow margin	-108.1%	Revenue: 34678000 Open source Operating Cash Flow: -35830000 Open source Capital Expenditure: 1657000 Open source
20142014-12-31	Free cash flow margin	-66.4%	Revenue: 60077000 Open source Operating Cash Flow: -39550000 Open source Capital Expenditure: 333000 Open source
20152015-12-31	Free cash flow margin	-591.2%	Revenue: 16116000 Open source Operating Cash Flow: -95203000 Open source Capital Expenditure: 78000 Open source
20162016-12-31	Free cash flow margin	-133.8%	Revenue: 57405000 Open source Operating Cash Flow: -76680000 Open source Capital Expenditure: 137000 Open source
20172017-12-31	Free cash flow margin	-156.5%	Revenue: 25146000 Open source Operating Cash Flow: -39296000 Open source Capital Expenditure: 49000 Open source
20182018-12-31	Free cash flow margin	-151.6%	Revenue: 26290000 Open source Operating Cash Flow: -39824000 Open source Capital Expenditure: 33000 Open source
20192019-12-31	Free cash flow margin	-831.7%	Revenue: 3345000 Open source Operating Cash Flow: -27822000 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -42205000 Open source Capital Expenditure: 17000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -84889000 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 53948000 Open source Operating Cash Flow: -81194000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -81.2M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	-35830000	Operating Cash Flow: -35830000 Open source
20142014-12-31	Operating cash flow	-39550000	Operating Cash Flow: -39550000 Open source
20152015-12-31	Operating cash flow	-95203000	Operating Cash Flow: -95203000 Open source
20162016-12-31	Operating cash flow	-76680000	Operating Cash Flow: -76680000 Open source
20172017-12-31	Operating cash flow	-39296000	Operating Cash Flow: -39296000 Open source
20182018-12-31	Operating cash flow	-39824000	Operating Cash Flow: -39824000 Open source
20192019-12-31	Operating cash flow	-27822000	Operating Cash Flow: -27822000 Open source
20202020-12-31	Operating cash flow	-42205000	Operating Cash Flow: -42205000 Open source
20212021-12-31	Operating cash flow	-84889000	Operating Cash Flow: -84889000 Open source
20222022-12-31	Operating cash flow	-81194000	Operating Cash Flow: -81194000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -84.9M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	-37487000	Operating Cash Flow: -35830000 Open source Capital Expenditure: 1657000 Open source
20142014-12-31	Free cash flow	-39883000	Operating Cash Flow: -39550000 Open source Capital Expenditure: 333000 Open source
20152015-12-31	Free cash flow	-95281000	Operating Cash Flow: -95203000 Open source Capital Expenditure: 78000 Open source
20162016-12-31	Free cash flow	-76817000	Operating Cash Flow: -76680000 Open source Capital Expenditure: 137000 Open source
20172017-12-31	Free cash flow	-39345000	Operating Cash Flow: -39296000 Open source Capital Expenditure: 49000 Open source
20182018-12-31	Free cash flow	-39857000	Operating Cash Flow: -39824000 Open source Capital Expenditure: 33000 Open source
20192019-12-31	Free cash flow	-27822000	Operating Cash Flow: -27822000 Open source Capital Expenditure: 0 Open source
20202020-12-31	Free cash flow	-42222000	Operating Cash Flow: -42205000 Open source Capital Expenditure: 17000 Open source
20212021-12-31	Free cash flow	-84889000	Operating Cash Flow: -84889000 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -81194000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

114% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Liabilities / assets	40%	Total Liabilities: 37504000 Open source Total Assets: 93723000 Open source
20142014-12-31	Liabilities / assets	56.7%	Total Liabilities: 52364000 Open source Total Assets: 92287000 Open source
20152015-12-31	Liabilities / assets	67.1%	Total Liabilities: 96784000 Open source Total Assets: 144197000 Open source
20162016-12-31	Liabilities / assets	87.8%	Total Liabilities: 56086000 Open source Total Assets: 63843000 Open source
20172017-12-31	Liabilities / assets	70.7%	Total Liabilities: 38796000 Open source Total Assets: 54886000 Open source
20182018-12-31	Liabilities / assets	41.1%	Total Liabilities: 36893000 Open source Total Assets: 89832000 Open source
20192019-12-31	Liabilities / assets	61.3%	Total Liabilities: 28350000 Open source Total Assets: 46280000 Open source
20202020-12-31	Liabilities / assets	31.3%	Total Liabilities: 18212000 Open source Total Assets: 58241000 Open source
20212021-12-31	Liabilities / assets	94.8%	Total Liabilities: 68667000 Open source Total Assets: 72434000 Open source
20222022-12-31	Liabilities / assets	114%	Total Liabilities: 143502000 Open source Total Assets: 125925000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.23× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	4.01×	Current Assets: 80515000 Open source Current Liabilities: 20069000 Open source
20142014-12-31	Current assets / current liabilities	2.22×	Current Assets: 80505000 Open source Current Liabilities: 36340000 Open source
20152015-12-31	Current assets / current liabilities	1.86×	Current Assets: 134975000 Open source Current Liabilities: 72409000 Open source
20162016-12-31	Current assets / current liabilities	1.37×	Current Assets: 55824000 Open source Current Liabilities: 40646000 Open source
20172017-12-31	Current assets / current liabilities	2.44×	Current Assets: 46924000 Open source Current Liabilities: 19258000 Open source
20182018-12-31	Current assets / current liabilities	3.58×	Current Assets: 82492000 Open source Current Liabilities: 23055000 Open source
20192019-12-31	Current assets / current liabilities	1.92×	Current Assets: 35580000 Open source Current Liabilities: 18488000 Open source
20202020-12-31	Current assets / current liabilities	3.19×	Current Assets: 54325000 Open source Current Liabilities: 17038000 Open source
20212021-12-31	Current assets / current liabilities	1.03×	Current Assets: 68379000 Open source Current Liabilities: 66651000 Open source
20222022-12-31	Current assets / current liabilities	1.23×	Current Assets: 99396000 Open source Current Liabilities: 81134000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 42.74 million Exact value Exact value: -42743000 USD 2013-01-01 – 2013-12-31: -42743000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2013-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -42743000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42743000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129316000105/ctic-20151231.xml#363950 Filing: 000089129316000105 The citation records this snapshot. The page link may show a newer release later.	−USD 35.83 million Exact value Exact value: -35830000 USD 2013-01-01 – 2013-12-31: -35830000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2013-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -35830000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35830000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129316000105/ctic-20151231.xml#363194 Filing: 000089129316000105 The citation records this snapshot. The page link may show a newer release later.	USD 1.66 million Exact value Exact value: 1657000 USD 2013-01-01 – 2013-12-31: 1657000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2013-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 1657000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1657000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129316000105/ctic-20151231.xml#384402 Filing: 000089129316000105 The citation records this snapshot. The page link may show a newer release later.	−USD 37.49 million Calculation and evidence -35830000 − 1657000 USD Exact free cash flow: -37487000 USD 2013-01-01 – 2013-12-31: -35830000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1657000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2013-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -37487000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35830000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129316000105/ctic-20151231.xml#363194 Filing: 000089129316000105 Input fundies:CapitalExpenditure: 1657000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129316000105/ctic-20151231.xml#384402 Filing: 000089129316000105 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 93.37 million Exact value Exact value: -93367000 USD 2014-01-01 – 2014-12-31: -93367000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2014-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -93367000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -93367000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129317000030/ctic-20161231.xml#351929 Filing: 000089129317000030 The citation records this snapshot. The page link may show a newer release later.	−USD 39.55 million Exact value Exact value: -39550000 USD 2014-01-01 – 2014-12-31: -39550000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2014-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -39550000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39550000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129317000030/ctic-20161231.xml#351173 Filing: 000089129317000030 The citation records this snapshot. The page link may show a newer release later.	USD 333,000 Exact value Exact value: 333000 USD 2014-01-01 – 2014-12-31: 333000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2014-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 333000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 333000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129317000030/ctic-20161231.xml#375131 Filing: 000089129317000030 The citation records this snapshot. The page link may show a newer release later.	−USD 39.88 million Calculation and evidence -39550000 − 333000 USD Exact free cash flow: -39883000 USD 2014-01-01 – 2014-12-31: -39550000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 333000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2014-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -39883000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39550000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129317000030/ctic-20161231.xml#351173 Filing: 000089129317000030 Input fundies:CapitalExpenditure: 333000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129317000030/ctic-20161231.xml#375131 Filing: 000089129317000030 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 119.42 million Exact value Exact value: -119422000 USD 2015-01-01 – 2015-12-31: -119422000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2015-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -119422000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -119422000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#325358 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	−USD 95.2 million Exact value Exact value: -95203000 USD 2015-01-01 – 2015-12-31: -95203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2015-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -95203000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -95203000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#324722 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	USD 78,000 Exact value Exact value: 78000 USD 2015-01-01 – 2015-12-31: 78000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2015-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 78000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 78000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#348506 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	−USD 95.28 million Calculation and evidence -95203000 − 78000 USD Exact free cash flow: -95281000 USD 2015-01-01 – 2015-12-31: -95203000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 78000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2015-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -95281000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -95203000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#324722 Filing: 000089129318000043 Input fundies:CapitalExpenditure: 78000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#348506 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 52.01 million Exact value Exact value: -52009000 USD 2016-01-01 – 2016-12-31: -52009000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2016-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -52009000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52009000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#326350 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	−USD 76.68 million Exact value Exact value: -76680000 USD 2016-01-01 – 2016-12-31: -76680000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2016-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -76680000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76680000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#324934 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	USD 137,000 Exact value Exact value: 137000 USD 2016-01-01 – 2016-12-31: 137000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2016-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 137000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 137000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#348714 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.	−USD 76.82 million Calculation and evidence -76680000 − 137000 USD Exact free cash flow: -76817000 USD 2016-01-01 – 2016-12-31: -76680000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 137000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2016-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -76817000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76680000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#324934 Filing: 000089129318000043 Input fundies:CapitalExpenditure: 137000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129318000043/ctic-20161231.xml#348714 Filing: 000089129318000043 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 40.67 million Exact value Exact value: -40670000 USD 2017-01-01 – 2017-12-31: -40670000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2017-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -40670000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40670000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/ctic-20181231.xml#246550 Filing: 000089129319000021 The citation records this snapshot. The page link may show a newer release later.	−USD 39.3 million Exact value Exact value: -39296000 USD 2017-01-01 – 2017-12-31: -39296000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2017-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -39296000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39296000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/ctic-20181231.xml#246126 Filing: 000089129319000021 The citation records this snapshot. The page link may show a newer release later.	USD 49,000 Exact value Exact value: 49000 USD 2017-01-01 – 2017-12-31: 49000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2017-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 49000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 49000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/ctic-20181231.xml#260626 Filing: 000089129319000021 The citation records this snapshot. The page link may show a newer release later.	−USD 39.35 million Calculation and evidence -39296000 − 49000 USD Exact free cash flow: -39345000 USD 2017-01-01 – 2017-12-31: -39296000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 49000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2017-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -39345000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39296000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/ctic-20181231.xml#246126 Filing: 000089129319000021 Input fundies:CapitalExpenditure: 49000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129319000021/ctic-20181231.xml#260626 Filing: 000089129319000021 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 29.32 million Exact value Exact value: -29320000 USD 2018-01-01 – 2018-12-31: -29320000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2018-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -29320000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29320000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/ctic-20191231.xml#206018 Filing: 000089129320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 39.82 million Exact value Exact value: -39824000 USD 2018-01-01 – 2018-12-31: -39824000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2018-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -39824000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39824000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/ctic-20191231.xml#205594 Filing: 000089129320000012 The citation records this snapshot. The page link may show a newer release later.	USD 33,000 Exact value Exact value: 33000 USD 2018-01-01 – 2018-12-31: 33000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2018-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 33000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 33000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/ctic-20191231.xml#220545 Filing: 000089129320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 39.86 million Calculation and evidence -39824000 − 33000 USD Exact free cash flow: -39857000 USD 2018-01-01 – 2018-12-31: -39824000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 33000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2018-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -39857000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39824000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/ctic-20191231.xml#205594 Filing: 000089129320000012 Input fundies:CapitalExpenditure: 33000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129320000012/ctic-20191231.xml#220545 Filing: 000089129320000012 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 40.02 million Exact value Exact value: -40020000 USD 2019-01-01 – 2019-12-31: -40020000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2019-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -40020000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40020000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129321000008/ctic-20201231.htm#743188 Filing: 000089129321000008 The citation records this snapshot. The page link may show a newer release later.	−USD 27.82 million Exact value Exact value: -27822000 USD 2019-01-01 – 2019-12-31: -27822000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2019-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -27822000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27822000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129321000008/ctic-20201231.htm#849372 Filing: 000089129321000008 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2019-01-01 – 2019-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2019-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129321000008/ctic-20201231.htm#852577 Filing: 000089129321000008 The citation records this snapshot. The page link may show a newer release later.	−USD 27.82 million Calculation and evidence -27822000 − 0 USD Exact free cash flow: -27822000 USD 2019-01-01 – 2019-12-31: -27822000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2019-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -27822000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27822000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129321000008/ctic-20201231.htm#849372 Filing: 000089129321000008 Input fundies:CapitalExpenditure: 0 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129321000008/ctic-20201231.htm#852577 Filing: 000089129321000008 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 52.45 million Exact value Exact value: -52451000 USD 2020-01-01 – 2020-12-31: -52451000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2020-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -52451000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52451000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#1439176 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 42.21 million Exact value Exact value: -42205000 USD 2020-01-01 – 2020-12-31: -42205000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2020-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -42205000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42205000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#892109 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.	USD 17,000 Exact value Exact value: 17000 USD 2020-01-01 – 2020-12-31: 17000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2020-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 17000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#895350 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 42.22 million Calculation and evidence -42205000 − 17000 USD Exact free cash flow: -42222000 USD 2020-01-01 – 2020-12-31: -42205000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 17000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2020-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -42222000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42205000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#892109 Filing: 000089129322000010 Input fundies:CapitalExpenditure: 17000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#895350 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 97.91 million Exact value Exact value: -97908000 USD 2021-01-01 – 2021-12-31: -97908000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2021-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -97908000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -97908000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#1490661 Filing: 000089129323000011 The citation records this snapshot. The page link may show a newer release later.	−USD 84.89 million Exact value Exact value: -84889000 USD 2021-01-01 – 2021-12-31: -84889000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2021-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -84889000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -84889000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#930481 Filing: 000089129323000011 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CELL THERAPEUTICS INC · 2021-12-31 CELL THERAPEUTICS INC (edgar:891293) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#894366 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.	−USD 84.89 million Calculation and evidence -84889000 − 0 USD Exact free cash flow: -84889000 USD 2021-01-01 – 2021-12-31: -84889000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CELL THERAPEUTICS INC · 2021-12-31 CELL THERAPEUTICS INC (edgar:891293) Free cash flow: -84889000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -84889000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#930481 Filing: 000089129323000011 Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129322000010/ctic-20211231.htm#894366 Filing: 000089129322000010 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 92.99 million Exact value Exact value: -92992000 USD 2022-01-01 – 2022-12-31: -92992000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CELL THERAPEUTICS INC · 2022-12-31 CELL THERAPEUTICS INC (edgar:891293) Net Income: -92992000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -92992000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#1489299 Filing: 000089129323000011 The citation records this snapshot. The page link may show a newer release later.	−USD 81.19 million Exact value Exact value: -81194000 USD 2022-01-01 – 2022-12-31: -81194000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CELL THERAPEUTICS INC · 2022-12-31 CELL THERAPEUTICS INC (edgar:891293) Operating Cash Flow: -81194000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T22:59:43Z Snapshot: 63b53071b74454f691eb4a6eed3f5ca5f3b340d416f0d7f41ccffdc1766e822e Dimensions: Consolidated View: https://fundies.io/companies/edgar/891293/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81194000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/891293/000089129323000011/ctic-20221231.htm#929432 Filing: 000089129323000011 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

148 filings · 3,720 latest values · 3,720 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000891293, 891293, CTIC, edgar:891293

Also known as CELL THERAPEUTICS INC, CTI BIOPHARMA CORP, CTI BIOPHARMA CORP.

CELL THERAPEUTICS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation